Cargando…

Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin

INTRODUCTION: Little is known regarding age-related risk of nephrotoxicity during vancomycin therapy after the publication of the 2009 vancomycin consensus guidelines for therapeutic drug monitoring. We sought to evaluate incidence and risk factors for acute kidney injury in three age groups. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Carreno, Joseph J., Jaworski, Anthony, Kenney, Rachel M., Davis, Susan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108114/
https://www.ncbi.nlm.nih.gov/pubmed/25134482
http://dx.doi.org/10.1007/s40121-013-0022-6
_version_ 1782327711787646976
author Carreno, Joseph J.
Jaworski, Anthony
Kenney, Rachel M.
Davis, Susan L.
author_facet Carreno, Joseph J.
Jaworski, Anthony
Kenney, Rachel M.
Davis, Susan L.
author_sort Carreno, Joseph J.
collection PubMed
description INTRODUCTION: Little is known regarding age-related risk of nephrotoxicity during vancomycin therapy after the publication of the 2009 vancomycin consensus guidelines for therapeutic drug monitoring. We sought to evaluate incidence and risk factors for acute kidney injury in three age groups. METHODS: Matched cohort study of patients receiving vancomycin, grouped by age: young adults (18–64 years), older adults (65–79 years) and very elderly (≥80 years), matched on previously published risk factors for nephrotoxicity. Outcomes included traditional vancomycin nephrotoxicity and Acute Kidney Injury Network-modified definition of nephrotoxicity. RESULTS: The incidence of acute kidney injury was 34.1% vs. 34.1% vs. 31.8% in the young, older adults and very elderly groups, respectively (p = 0.97). In the logistic regression model, after adjusting for baseline risk factors, age was not a significant predictor of acute kidney injury. Lower respiratory tract infection (adjusted odds ratio [aOR] 5.18; 95% confidence interval [CI] 2.15–12.41) and duration of treatment (aOR 1.12; 95% CI 1.03–1.22) were found to be independently associated with outcome. CONCLUSION: No differences in risk of acute kidney injury were identified between young, older, and very elderly adults when adjusting for other risk factors. Further research is required to identify strategies to optimize the safety of vancomycin in the aging population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-013-0022-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4108114
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-41081142014-07-24 Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin Carreno, Joseph J. Jaworski, Anthony Kenney, Rachel M. Davis, Susan L. Infect Dis Ther Original Research INTRODUCTION: Little is known regarding age-related risk of nephrotoxicity during vancomycin therapy after the publication of the 2009 vancomycin consensus guidelines for therapeutic drug monitoring. We sought to evaluate incidence and risk factors for acute kidney injury in three age groups. METHODS: Matched cohort study of patients receiving vancomycin, grouped by age: young adults (18–64 years), older adults (65–79 years) and very elderly (≥80 years), matched on previously published risk factors for nephrotoxicity. Outcomes included traditional vancomycin nephrotoxicity and Acute Kidney Injury Network-modified definition of nephrotoxicity. RESULTS: The incidence of acute kidney injury was 34.1% vs. 34.1% vs. 31.8% in the young, older adults and very elderly groups, respectively (p = 0.97). In the logistic regression model, after adjusting for baseline risk factors, age was not a significant predictor of acute kidney injury. Lower respiratory tract infection (adjusted odds ratio [aOR] 5.18; 95% confidence interval [CI] 2.15–12.41) and duration of treatment (aOR 1.12; 95% CI 1.03–1.22) were found to be independently associated with outcome. CONCLUSION: No differences in risk of acute kidney injury were identified between young, older, and very elderly adults when adjusting for other risk factors. Further research is required to identify strategies to optimize the safety of vancomycin in the aging population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-013-0022-6) contains supplementary material, which is available to authorized users. Springer Healthcare 2013-12-11 2013-12 /pmc/articles/PMC4108114/ /pubmed/25134482 http://dx.doi.org/10.1007/s40121-013-0022-6 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Carreno, Joseph J.
Jaworski, Anthony
Kenney, Rachel M.
Davis, Susan L.
Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title_full Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title_fullStr Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title_full_unstemmed Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title_short Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin
title_sort comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108114/
https://www.ncbi.nlm.nih.gov/pubmed/25134482
http://dx.doi.org/10.1007/s40121-013-0022-6
work_keys_str_mv AT carrenojosephj comparativeincidenceofnephrotoxicitybyagegroupamongadultpatientsreceivingvancomycin
AT jaworskianthony comparativeincidenceofnephrotoxicitybyagegroupamongadultpatientsreceivingvancomycin
AT kenneyrachelm comparativeincidenceofnephrotoxicitybyagegroupamongadultpatientsreceivingvancomycin
AT davissusanl comparativeincidenceofnephrotoxicitybyagegroupamongadultpatientsreceivingvancomycin